Percutaneous Extracorporeal Ventricular Assist Device as a Successful Bridge Strategy to Durable Left Ventricular Assist Device in Refractory Cardiogenic Shock: A Case Report - Scorecard - MDSpire
Advertisement
Percutaneous Extracorporeal Ventricular Assist Device as a Successful Bridge Strategy to Durable Left Ventricular Assist Device in Refractory Cardiogenic Shock: A Case Report
Clinical Scorecard: Successful Use of a Percutaneous Extracorporeal Ventricular Assist Device as a Transitional Solution to Permanent Left Ventricular Assist Device in Patients with Refractory Cardiogenic Shock: A Case Study
At a Glance
Category
Detail
Condition
Refractory Cardiogenic Shock
Key Mechanisms
Temporary mechanical circulatory support (tMCS) using a percutaneous extracorporeal VAD to alleviate left ventricular load.
Target Population
Patients with refractory cardiogenic shock, particularly those unsuitable for immediate durable LVAD implantation.
Care Setting
Hospital settings capable of performing minimally invasive procedures.
Key Highlights
Successful bridging to durable LVAD therapy using a percutaneous extracorporeal VAD.
Minimally invasive technique performed without complications.
Rapid patient improvement observed after deployment.
Facilitates early mobilization and streamlines postoperative management.
Cost-effective alternative in regions with limited access to advanced devices.
Guideline-Based Recommendations
Diagnosis
Assess hemodynamic instability and signs of severe cardiogenic shock.
Management
Consider percutaneous extracorporeal VAD as a bridge to durable LVAD or transplantation.
Monitoring & Follow-up
Continuous monitoring of hemodynamics and potential complications during tMCS.
Risks
Potential complications associated with mechanical support devices, including infection and device malfunction.
Patient & Prescribing Data
High-risk patients with refractory cardiogenic shock.
Percutaneous extracorporeal VAD provides effective temporary support while awaiting durable solutions.
Clinical Best Practices
Utilize percutaneous techniques to minimize complications.
Implement early mobilization strategies for improved outcomes.
Ensure multidisciplinary team involvement for optimal patient management.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
